Blueprint Medicines Corporation
Symboli: 0HOJ.L
LSE
103.975
USDMarkkinahinta tänään
-21.9523
P/E-suhde
-1.5084
PEG-suhde
6.51B
MRK Cap
- 0.00%
DIV Tuotto
Blueprint Medicines Corporation (0HOJ-L) Tilinpäätöstiedotteet
Tase
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 2794.16 | 710.6 | 1078.5 | 1034.6 | |||||||||||
balance-sheet.row.short-term-investments | 2478.05 | 639.4 | 825.3 | 267.2 | |||||||||||
balance-sheet.row.net-receivables | 182.75 | 43.2 | 36.9 | 37 | |||||||||||
balance-sheet.row.inventory | 85.64 | 21.2 | 29.7 | 21.8 | |||||||||||
balance-sheet.row.other-current-assets | 141.96 | 33.4 | 35 | -539.5 | |||||||||||
balance-sheet.row.total-current-assets | 3204.5 | 808.4 | 1046.7 | 554 | |||||||||||
balance-sheet.row.property-plant-equipment-net | 459.14 | 115.7 | 115.2 | 120.9 | |||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.long-term-investments | 520.48 | 94.6 | 161.3 | 557.5 | |||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-non-current-assets | 115.34 | 30.6 | 26.8 | 19.8 | |||||||||||
balance-sheet.row.total-non-current-assets | 1094.97 | 240.9 | 303.3 | 698.2 | |||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-assets | 4299.47 | 1049.3 | 1349.9 | 1252.2 | |||||||||||
balance-sheet.row.account-payables | 23.58 | 4.7 | 2.7 | 8.3 | |||||||||||
balance-sheet.row.short-term-debt | 303.09 | 81.4 | 27.4 | 8.1 | |||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.long-term-debt-total | 2187.5 | 611 | 215 | 103.3 | |||||||||||
Deferred Revenue Non Current | 19.43 | 4.8 | 426.7 | 25.1 | |||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 331.32 | - | - | - | |||||||||||
balance-sheet.row.other-current-liab | 446.87 | 128 | -295.5 | 96.8 | |||||||||||
balance-sheet.row.total-non-current-liabilities | 2556.49 | 703.7 | 652 | 131.7 | |||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.capital-lease-obligations | 331.32 | 81.8 | 103.4 | 111.4 | |||||||||||
balance-sheet.row.total-liab | 3344.43 | 918.6 | 835.2 | 281.5 | |||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.common-stock | 0.25 | 0.1 | 0.1 | 0.1 | |||||||||||
balance-sheet.row.retained-earnings | -8915.08 | -2339.9 | -1833 | -1275.4 | |||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -14.25 | -3.5 | -10.4 | -4.1 | |||||||||||
balance-sheet.row.other-total-stockholders-equity | 9884.12 | 2474 | 2358 | 2250.3 | |||||||||||
balance-sheet.row.total-stockholders-equity | 955.04 | 130.6 | 514.7 | 970.7 | |||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 4299.47 | 1049.3 | 1349.9 | 1252.2 | |||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-equity | 955.04 | 130.6 | 514.7 | 970.7 | |||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 4299.47 | - | - | - | |||||||||||
Total Investments | 2998.53 | 733.9 | 958.8 | 824.7 | |||||||||||
balance-sheet.row.total-debt | 2821.92 | 774.1 | 242.5 | 111.4 | |||||||||||
balance-sheet.row.net-debt | 2505.81 | 702.8 | 122.7 | -98.5 |
Kassavirtalaskelma
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -288.29 | -507 | -557.5 | -644.1 | |||||||||||
cash-flows.row.depreciation-and-amortization | 17.35 | 11.7 | 20.1 | 12.8 | |||||||||||
cash-flows.row.deferred-income-tax | -59.6 | -126.1 | -87.8 | -67.3 | |||||||||||
cash-flows.row.stock-based-compensation | 93.7 | 92.7 | 99 | 91.6 | |||||||||||
cash-flows.row.change-in-working-capital | -57.91 | -41.1 | -53.8 | -23.7 | |||||||||||
cash-flows.row.account-receivables | -29.94 | -7.7 | -2.2 | -11.8 | |||||||||||
cash-flows.row.inventory | -1.75 | -4.4 | -8.9 | -12.6 | |||||||||||
cash-flows.row.account-payables | -5.61 | 1.9 | -5.8 | 4.2 | |||||||||||
cash-flows.row.other-working-capital | -20.61 | -31 | -36.8 | -3.5 | |||||||||||
cash-flows.row.other-non-cash-items | -14.55 | 133.1 | 77.8 | 332 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -415.4 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -14.58 | -16.1 | -8.9 | -3.1 | |||||||||||
cash-flows.row.acquisitions-net | -114.73 | -290.1 | 0 | -258.2 | |||||||||||
cash-flows.row.purchases-of-investments | -833.65 | -766.4 | -489.7 | -655.4 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 1026.62 | 1056.5 | 349.4 | 690.8 | |||||||||||
cash-flows.row.other-investing-activites | 192.96 | 290.1 | -0.3 | 0 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 178.38 | 274 | -149.5 | -225.9 | |||||||||||
cash-flows.row.debt-repayment | -98.37 | -97.9 | -553.6 | 0 | |||||||||||
cash-flows.row.common-stock-issued | 88.67 | 21.3 | 8.2 | 50.7 | |||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.other-financing-activites | 103.28 | 0 | 424 | 50.7 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 186.19 | 119.2 | 561.8 | 50.7 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | -0.14 | 0.2 | -0.2 | -0.9 | |||||||||||
cash-flows.row.net-change-in-cash | -56.4 | -48.4 | -90.2 | -474.7 | |||||||||||
cash-flows.row.cash-at-end-of-period | 316.11 | 71.3 | 119.7 | 209.9 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 372.51 | 119.7 | 209.9 | 684.6 | |||||||||||
cash-flows.row.operating-cash-flow | -415.4 | -436.8 | -502.3 | -298.7 | |||||||||||
cash-flows.row.capital-expenditure | -14.58 | -16.1 | -8.9 | -3.1 | |||||||||||
cash-flows.row.free-cash-flow | -429.98 | -452.9 | -511.2 | -301.7 |
Tuloslaskelmarivi
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 282.21 | 249.4 | 204 | 180.1 | |||||||||||
income-statement-row.row.cost-of-revenue | 28.91 | 24.5 | 46.9 | 38.5 | |||||||||||
income-statement-row.row.gross-profit | 253.3 | 224.9 | 157.2 | 141.6 | |||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.research-development | 393.25 | - | - | - | |||||||||||
income-statement-row.row.selling-general-administrative | 62.37 | - | - | - | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 16.9 | - | - | - | |||||||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.operating-expenses | 694.19 | 711.2 | 694.7 | 783.5 | |||||||||||
income-statement-row.row.cost-and-expenses | 723.1 | 735.7 | 741.6 | 822.1 | |||||||||||
income-statement-row.row.interest-income | 36.09 | 32.8 | 17.7 | 2.4 | |||||||||||
income-statement-row.row.interest-expense | 54.96 | 51.6 | 16.8 | 0 | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 16.9 | - | - | - | |||||||||||
income-statement-row.row.total-other-income-expensenet | 153.23 | -19.7 | -14.8 | 0.9 | |||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.total-operating-expenses | 153.23 | -19.7 | -14.8 | 0.9 | |||||||||||
income-statement-row.row.interest-expense | 54.96 | 51.6 | 16.8 | 0 | |||||||||||
income-statement-row.row.depreciation-and-amortization | 17.35 | 11.7 | 20.1 | 12.8 | |||||||||||
income-statement-row.row.ebitda-caps | -423.55 | - | - | - | |||||||||||
income-statement-row.row.operating-income | -440.89 | -486.3 | -537.5 | -642 | |||||||||||
income-statement-row.row.income-before-tax | -287.66 | -506 | -552.3 | -641.1 | |||||||||||
income-statement-row.row.income-tax-expense | 0.63 | 1 | 5.2 | 3 | |||||||||||
income-statement-row.row.net-income | -288.29 | -507 | -557.5 | -644.1 |
Usein kysytty kysymys
Mikä on Blueprint Medicines Corporation (0HOJ.L) taseen loppusumma?
Blueprint Medicines Corporation (0HOJ.L) kokonaisvarat ovat 1049250000.000.
Mikä on yrityksen vuotuinen liikevaihto?
Vuotuinen liikevaihto on 168073000.000.
Mikä on yrityksen voittomarginaali?
Yrityksen voittomarginaali on 0.898.
Mikä on yrityksen vapaa kassavirta?
Vapaa kassavirta on -6.982.
Mikä on yrityksen nettovoittomarginaali?
Nettovoittomarginaali on -1.022.
Mikä on yrityksen kokonaistulot?
Kokonaisliikevaihto on -1.562.
Mikä on Blueprint Medicines Corporation (0HOJ.L) nettovoitto (nettotulos)?
Nettovoitto (nettotulos) on -506984000.000.
Mikä on yrityksen kokonaisvelka?
Kokonaisvelka on 774122000.000.
Mikä on yrityksen toimintakulujen määrä?
Toimintakulut ovat 711196000.000.
Mikä on yrityksen kassan määrä?
Yrityksen kassavarat ovat 113326000.000.